BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Provided By GlobeNewswire
Last update: Sep 23, 2024
Context to obtain exclusive development and commercialization rights to BA3362
BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales
Read more at globenewswire.com0.9428
+0.11 (+13.05%)
Find more stocks in the Stock Screener
CNTX Latest News and Analysis
19 days ago - ChartmillUnusual volume stocks in Friday's sessionLet's explore the current happenings on the US markets on Friday. Below, you'll find the stocks exhibiting unusual volume in today's session.
20 days ago - ChartmillThese stocks that are showing activity before the opening bell on Thursday.The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
